The evolving treatment landscape in HER2-mutant NSCLC

I am a board-certified hematologist and medical oncologist at UF Health, with 12 years of experience in academia and community oncology practice. It is my goal to apply both research and science toward providing equitable lung cancer care. I believe in providing the highest quality of care for patients-like I would want for myself and my loved ones.

I previously served as the section chief of oncology at the Birmingham VA Medical Center. I was also principal investigator for the lung precision oncology programme for veterans and served as the site director for the state veterans’ lung cancer screening program, along with other leadership roles.

I have experience as a medical educator, having served as a fellowship site director and associate fellowship program director, among other roles in health care education.

My research interests include designing and implementing high-quality clinical trials that are equitable and patient-centric, with a focus on enrolling those who are historically underrepresented in medicine.

Most recently, I was medical director for solid tumor oncology trials with Parexel and am currently an associate professor of medicine, disease group lead for thoracic oncology, and division director of quality and safety at the University of Florida in Gainesville. In this role, I focus on delivering the highest-quality clinical trials in lung cancer and enhancing the implementation of the lung cancer screening programme.

Dr Thomas Newsom-Davis BSc MBBS FRCP, PhD

Tom Newsom-Davis is a consultant thoracic medical oncologist at Chelsea and Westminster Hospital, London, and an Honorary Consultant at the Royal Brompton Hospital, London.  

Dr Newsom-Davis has an active clinical trials portfolio. He has been UK Chief Investigator for a number of studies, as well as chairing Independent Data Monitoring Committees and sitting on trial steering groups. He has published over 70 papers and presented more than 120 abstracts in national and international meetings.

Dr Newsom-Davis joined the steering committee of the British Thoracic Oncology Group (BTOG) in 2017, as was elected Chair in 2025. He serves on the Multidisciplinary Clinical Science Committee of the International Association for the Study of Lung Cancer (IASLC), on the Oncology Council of the Royal Society of Medicine, and as an invited clinic expert for NICE. Dr Newsom-Davis is past Chair of the RM Partners Cancer Alliance Lung group, and past member of the NCRI Lung Cancer Clinical Studies Group.

He has been an invited lecturer for various organisations including the Royal College of Physicians, European Society of Medical Oncology (ESMO), IASLC, British Medical Association and the Association of Cancer Physicians. He has been a faculty member for ESMO and IASLC. His work on Acute Diagnostic Oncology Clinics has previously been awarded a Macmillan Innovation Excellence Award.

I am a board-certified hematologist and medical oncologist at UF Health, with 12 years of experience in academia and community oncology practice. It is my goal to apply both research and science toward providing equitable lung cancer care. I believe in providing the highest quality of care for patients-like I would want for myself and my loved ones.

I previously served as the section chief of oncology at the Birmingham VA Medical Center. I was also principal investigator for the lung precision oncology programme for veterans and served as the site director for the state veterans’ lung cancer screening program, along with other leadership roles.

I have experience as a medical educator, having served as a fellowship site director and associate fellowship program director, among other roles in health care education.

My research interests include designing and implementing high-quality clinical trials that are equitable and patient-centric, with a focus on enrolling those who are historically underrepresented in medicine.

Most recently, I was medical director for solid tumor oncology trials with Parexel and am currently an associate professor of medicine, disease group lead for thoracic oncology, and division director of quality and safety at the University of Florida in Gainesville. In this role, I focus on delivering the highest-quality clinical trials in lung cancer and enhancing the implementation of the lung cancer screening programme.

Dr Thomas Newsom-Davis BSc MBBS FRCP, PhD

Tom Newsom-Davis is a consultant thoracic medical oncologist at Chelsea and Westminster Hospital, London, and an Honorary Consultant at the Royal Brompton Hospital, London.  

Dr Newsom-Davis has an active clinical trials portfolio. He has been UK Chief Investigator for a number of studies, as well as chairing Independent Data Monitoring Committees and sitting on trial steering groups. He has published over 70 papers and presented more than 120 abstracts in national and international meetings.

Dr Newsom-Davis joined the steering committee of the British Thoracic Oncology Group (BTOG) in 2017, as was elected Chair in 2025. He serves on the Multidisciplinary Clinical Science Committee of the International Association for the Study of Lung Cancer (IASLC), on the Oncology Council of the Royal Society of Medicine, and as an invited clinic expert for NICE. Dr Newsom-Davis is past Chair of the RM Partners Cancer Alliance Lung group, and past member of the NCRI Lung Cancer Clinical Studies Group.

He has been an invited lecturer for various organisations including the Royal College of Physicians, European Society of Medical Oncology (ESMO), IASLC, British Medical Association and the Association of Cancer Physicians. He has been a faculty member for ESMO and IASLC. His work on Acute Diagnostic Oncology Clinics has previously been awarded a Macmillan Innovation Excellence Award.